Amneal Pharmaceuticals (AMRX) Short term Debt (2017 - 2026)

Amneal Pharmaceuticals has reported Short term Debt for 10 years, with the latest figure at $100.0 million in Q2 2026.

• On a quarterly basis, Short term Debt fell 65.52% year-over-year to $100.0 million in Q2 2026; TTM through Jun 2026 was $100.0 million, a 65.52% decrease from a year earlier, with the FY2025 full-year figure at $6.8 million, down 96.98% from the prior year.
• Short term Debt was $100.0 million for Q2 2026 at Amneal Pharmaceuticals, up from $6.2 million in the prior quarter.
• The five-year high for Short term Debt was $290.0 million in Q1 2025, with the low at $6.2 million in Q1 2026.
• Average Short term Debt over 5 years is $125.8 million, with a median of $100.0 million recorded in 2023.
• The sharpest annual moves came in 2023 and 2026: Short term Debt soared 227.62% in 2023, then slumped 97.86% in 2026.
• Over 5 years, Short term Debt stood at $60.0 million in 2022, then jumped by 198.33% to $179.0 million in 2023, then grew by 25.26% to $224.2 million in 2024, then sank by 96.98% to $6.8 million in 2025, then soared by 1379.07% to $100.0 million in 2026.
• The last three Short term Debt figures came in at $100.0 million (Q2 2026), $6.2 million (Q1 2026), and $6.8 million (Q4 2025), per Business Quant data.